More than two dozen Senate Democrats have launched an investigation into the U.S. Environmental Protection Agency (EPA) after the agency stopped assigning a dollar value to the health benefits of reducing air pollution.
What Changed?
In a recent regulatory analysis, the EPA said it will no longer monetize the health benefits tied to limits on fine particulate matter (PM2.5) and ozone, citing uncertainty in economic estimates.
Previously, the agency quantified benefits such as avoided premature deaths, asthma attacks and hospitalizations — figures used to weigh public health gains against industry compliance costs.
Democrats argue the move could skew future rulemaking in favor of polluting industries by focusing only on regulatory costs while ignoring health benefits.
Senate Investigation Underway
The effort is led by Sen. Sheldon Whitehouse, ranking member of the Senate Environment and Public Works Committee. Lawmakers have requested documents explaining how the EPA reached its decision and whether outside parties were consulted.
In a letter to the agency, senators called the policy “irrational” and warned it could lead to rejecting actions that impose “relatively minor costs” on industry but deliver “massive benefits” to public health.
Experts Raise Red Flags
Environmental law experts say the decision marks a sharp departure from decades of bipartisan precedent. Traditionally, cost-benefit analysis — formalized under Executive Order 12866 signed by President Bill Clinton — has required agencies to rigorously quantify both costs and benefits.
Critics argue the EPA’s updated analysis lacked scientific citations, peer review and consultation with its Science Advisory Board.
Why It Matters
PM2.5 (soot) and ozone (smog) are among the most harmful air pollutants in the U.S., linked to respiratory illness, heart disease and premature death. In past analyses, the EPA estimated that stricter particulate standards could prevent up to 4,500 premature deaths annually and generate tens of billions of dollars in health benefits.
Under the new framework, those monetized health estimates will no longer factor into regulatory decisions.
An EPA spokesperson said the agency remains committed to protecting human health but will not monetize health impacts “at this time.”
Democrats and public health experts warn the shift could make it easier to weaken air pollution controls — by removing the economic value assigned to cleaner air.
For more on environmental policies, stay tuned to Que Onda Magazine.